JP6876680B2 - ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント - Google Patents

ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント Download PDF

Info

Publication number
JP6876680B2
JP6876680B2 JP2018510109A JP2018510109A JP6876680B2 JP 6876680 B2 JP6876680 B2 JP 6876680B2 JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018510109 A JP2018510109 A JP 2018510109A JP 6876680 B2 JP6876680 B2 JP 6876680B2
Authority
JP
Japan
Prior art keywords
sf3b1
cancer
splicing
seq
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525994A (ja
JP2018525994A5 (enExample
Inventor
リーファ ユー，
リーファ ユー，
キアン， ヒュ リム，
キアン， ヒュ リム，
ジャコブ， ディー． フィアラ，
ジャコブ， ディー． フィアラ，
シルヴィア ブオナミーチ，
シルヴィア ブオナミーチ，
佳治 水井
佳治 水井
ピーター， ジー． スミス，
ピーター， ジー． スミス，
ピン ズー，
ピン ズー，
ユニス， サン パク，
ユニス， サン パク，
マイケル， ダブリュー． セイラー，
マイケル， ダブリュー． セイラー，
マルコ， ピーター フェッケス，
マルコ， ピーター フェッケス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2018525994A publication Critical patent/JP2018525994A/ja
Publication of JP2018525994A5 publication Critical patent/JP2018525994A5/ja
Priority to JP2021074145A priority Critical patent/JP7256840B2/ja
Application granted granted Critical
Publication of JP6876680B2 publication Critical patent/JP6876680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2018510109A 2015-09-01 2016-08-30 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント Active JP6876680B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021074145A JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212876P 2015-09-01 2015-09-01
US62/212,876 2015-09-01
PCT/US2016/049490 WO2017040526A2 (en) 2015-09-01 2016-08-30 Splice variants associated with neomorphic sf3b1 mutants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021074145A Division JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Publications (3)

Publication Number Publication Date
JP2018525994A JP2018525994A (ja) 2018-09-13
JP2018525994A5 JP2018525994A5 (enExample) 2019-10-10
JP6876680B2 true JP6876680B2 (ja) 2021-05-26

Family

ID=56936518

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018510109A Active JP6876680B2 (ja) 2015-09-01 2016-08-30 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
JP2021074145A Active JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021074145A Active JP7256840B2 (ja) 2015-09-01 2021-04-26 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Country Status (5)

Country Link
US (2) US10889866B2 (enExample)
EP (2) EP3910073B1 (enExample)
JP (2) JP6876680B2 (enExample)
ES (1) ES2887201T3 (enExample)
WO (1) WO2017040526A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3910073B1 (en) 2015-09-01 2024-03-06 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
SG11201907887SA (en) * 2017-03-15 2019-09-27 Eisai Co Ltd Spliceosome mutations and uses thereof
US12098172B2 (en) 2017-07-31 2024-09-24 The Johns Hopkins University Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations
JOP20200243A1 (ar) * 2018-04-09 2020-09-29 Eisai R&D Man Co Ltd مركبات البلاديينوليد واستخداماتها
IL278740B2 (en) 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
JP6931860B2 (ja) * 2019-02-08 2021-09-08 株式会社Ｚｅｎｉｃｋ ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム
US20220073971A1 (en) * 2019-02-08 2022-03-10 Zenick Corporation Method for analyzing mrna precursor, information processing apparatus, and computer program
WO2020264177A1 (en) * 2019-06-26 2020-12-30 Fred Hutchinson Cancer Research Center Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders
CN111518805A (zh) * 2020-04-30 2020-08-11 北京航空航天大学 一种可用于抑制肿瘤增殖的非编码基因及其应用
ES2891182A1 (es) * 2020-07-14 2022-01-26 Servicio Andaluz De Salud Compuestos para el tratamiento del carcinoma hepatocelular
TW202233187A (zh) 2020-11-04 2022-09-01 日商衛材R&D企管股份有限公司 骨髓發育不良症候群（ｍｄｓ）之生物標記物及其使用方法
CN116507334A (zh) * 2020-11-04 2023-07-28 卫材R&D管理有限公司 骨髓增生异常综合征（mds）的生物标记物及其使用方法
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023209074A1 (en) * 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
CN1178973C (zh) 2000-02-18 2004-12-08 甘瑟尔股份有限公司 官能化聚亚烷基亚胺的制备方法,含有它们的组合物及其应用
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7576204B2 (en) 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
JP4328293B2 (ja) 2002-07-31 2009-09-09 メルシャン株式会社 新規生理活性物質
EP1580278A4 (en) 2002-11-29 2010-08-25 Mercian Corp METHOD FOR PRODUCING A MAKROLIDE COMPOUND
KR20060110865A (ko) 2003-11-27 2006-10-25 에자이 가부시키가이샤 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ
JP4599357B2 (ja) 2004-07-20 2010-12-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ
JPWO2007043621A1 (ja) 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法
US20100021918A1 (en) * 2007-03-05 2010-01-28 Eisai R&D Management Co., Ltd. Method for assaying action of antitumor agent using splicing defects as index
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
ES2614810T3 (es) 2008-08-14 2017-06-02 Nanostring Technologies, Inc Nanoindicadores estables
WO2011129427A1 (ja) * 2010-04-16 2011-10-20 第一三共株式会社 癌の診断剤および治療剤
EP2776830B1 (en) 2011-11-08 2018-05-09 Genomic Health, Inc. Method of predicting breast cancer prognosis
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
JP6057408B2 (ja) 2012-03-05 2017-01-11 国立大学法人 千葉大学 癌の予防剤および／または治療剤
US20140275010A1 (en) 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
WO2014165753A1 (en) 2013-04-05 2014-10-09 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof
PL3143016T3 (pl) 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Związki i sposoby zastosowania pladienolidu pirydyny
EP3910073B1 (en) 2015-09-01 2024-03-06 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants

Also Published As

Publication number Publication date
WO2017040526A3 (en) 2017-04-20
EP3344780A2 (en) 2018-07-11
EP3910073B1 (en) 2024-03-06
JP7256840B2 (ja) 2023-04-12
US10889866B2 (en) 2021-01-12
ES2887201T3 (es) 2021-12-22
US20210130909A1 (en) 2021-05-06
EP3910073A1 (en) 2021-11-17
EP3344780B1 (en) 2021-06-23
WO2017040526A2 (en) 2017-03-09
JP2021106615A (ja) 2021-07-29
JP2018525994A (ja) 2018-09-13
US20180318312A1 (en) 2018-11-08
US11761045B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
JP6876680B2 (ja) ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
JP5421374B2 (ja) 悪性神経膠腫におけるイソクエン酸デヒドロゲナーゼ遺伝子および他の遺伝子の遺伝子変化
JP7519125B2 (ja) 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法
US20170198353A1 (en) Kras mutations and resistance to anti-egfr treatment
CN106434870A (zh) ncRNA及其用途
WO2017079632A1 (en) Patient-derived ctc-xenograft models
Li et al. Cancer-associated fibroblasts foster a high-lactate microenvironment to drive perineural invasion in pancreatic cancer
Li et al. Mutant ACTB mRNA 3′-UTR promotes hepatocellular carcinoma development by regulating miR-1 and miR-29a
JP2006523456A (ja) 分子細胞遺伝学的方法を用いる癌連鎖遺伝子および治療標的の確認
CA3186353A1 (en) Prognostic biomarkers for cancer
Zeng et al. MALAT1 promotes FOXA1 degradation by competitively binding to miR-216a-5p and enhancing neuroendocrine differentiation in prostate cancer
CN107148481A (zh) 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法
CN115807082B (zh) lncRNA LINREP在胶质瘤诊断、预后和治疗中的应用
KR20210144353A (ko) 단일세포 전사체 분석에 기반한 대장암의 예후 예측 방법
EP3464623B1 (en) Androgen receptor splice variants and androgen deprivation therapy
CN111979315A (zh) 环状tp63作为肺鳞癌诊断或治疗靶点的应用
HK40063437B (en) Splice variants associated with neomorphic sf3b1 mutants
HK40063437A (en) Splice variants associated with neomorphic sf3b1 mutants
CN112795651B (zh) Muc20作为诊断多发性套细胞淋巴瘤蛋白酶体抑制剂耐药的标志物及其应用
KR101370108B1 (ko) 위암 진단용 마커로서 ｈｄａｃ2의 용도
Tüns High-throughput analyses for the identification of progression-specific factors in non-small-cell lung cancer
Lu et al. RPL34-Divergent Transcript, a Novel Long NonCoding Ribonucleic Acid, Promotes Migration by Activating Epithelial-Mesenchymal Transition in Glioma
WO2024196792A2 (en) Identification of selective regulators of oncogene translation
CN120536430A (zh) 一种分离的Circ_CIT基因序列、基于实时荧光定量PCR检测鼻咽癌相关基因表达水平的方法及试剂盒
CN121136952A (zh) 一种胶质瘤生物标志物、alg1及其抑制剂的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210426

R150 Certificate of patent or registration of utility model

Ref document number: 6876680

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6876680

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250